HERON THERAPEUTICS INC (HRTX) Stock Price, Quote, News and Overview
NASDAQ:HRTX - Nasdaq - US4277461020 - Common Stock - Currency: USD
HRTX Quote, Performance and Key Statistics
HERON THERAPEUTICS INC
NASDAQ:HRTX (2/5/2025, 11:31:13 AM)
1.8
-0.01 (-0.55%)
The current stock price of HRTX is 1.8 USD. In the past month the price increased by 9.04%. In the past year, price decreased by -25.51%.
HRTX Latest News, Press Releases and Analysis
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of...
U.S. District Court Upholds Validity of CINVANTI® Patents
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S....
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results...
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its...
HRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.94 | 338.76B | ||
| AMGN | AMGEN INC | 15.36 | 163.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.48 | 125.76B | ||
| GILD | GILEAD SCIENCES INC | 22.59 | 124.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.55 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.50B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.59B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.44B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.96 | 21.33B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.75B |
Related stock screener links
About HRTX
Company Profile
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 126 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Company Info
HERON THERAPEUTICS INC
4242 Campus Point Court, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Barry Quart
Employees: 126
Company Website: https://www.herontx.com/
Investor Relations: https://herontherapeutics.gcs-web.com
Phone: 18582514400
HRTX FAQ
What is the stock price of HRTX?
The current stock price of HRTX is 1.8 USD.
What is the symbol for HERON THERAPEUTICS INC stock?
The exchange symbol of HERON THERAPEUTICS INC is HRTX and it is listed on the Nasdaq exchange.
On which exchange is HRTX stock listed?
HRTX stock is listed on the Nasdaq exchange.
Is HRTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for HRTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of HRTX.
Does HRTX stock pay dividends?
HRTX does not pay a dividend.
When does HRTX stock report earnings?
HRTX will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of HRTX?
HRTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
What is the Short Interest ratio of HRTX stock?
The outstanding short interest for HRTX is 20.57% of its float.
HRTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to HRTX. When comparing the yearly performance of all stocks, HRTX is a bad performer in the overall market: 79.48% of all stocks are doing better.
HRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HRTX. Both the profitability and financial health of HRTX have multiple concerns.
HRTX Financial Highlights
Over the last trailing twelve months HRTX reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 81.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to HRTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 85.37% and a revenue growth 13.8% for HRTX